Researchers focused on accelerating and testing new treatments for low-grade brain tumours are set to receive a transformative £2.8million to drive their future work.
The Brain Tumour Research Centre of Excellence at the University of Plymouth is a hub for world-leading research into low-grade tumours including low-grade glioma, meningioma, and schwannoma.
There are currently limited treatment options for these types of tumour beyond surgery and radiotherapy, both of which come with many side effects.
The five-year funding from the charity Brain Tumour Research support will enable scientists to deepen their understanding of how these tumours develop and translate that knowledge into life-changing therapies. After the first three years, the Centre will undergo an expert review designed to track progress and strengthen its impact.
The new investment builds on a partnership between Brain Tumour Research and the University of Plymouth which first began in 2014.
Leading this new phase of work is
[STAFFMEMBER]
"> Professor David Parkinson, Professor of Neuroscience at the University of Plymouth and the newly appointed Director of the Brain Tumour Research Centre of Excellence. Under his leadership, the Centre will continue bringing together scientists, clinicians, and experts from multiple disciplines to improve outcomes for patients and offer renewed hope to families affected by brain tumours.
/University Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
